Catherine Brenner

This paper identifies M30-E05, an engineered flavonoid that disrupts the AIF/CHCHD4 mitochondrial complex, reducing cancer cell viability and tumor growth in xenograft models.

This study identifies a metabolic vulnerability in osteosarcoma by combining AIF/CHCHD4 inhibition and GLS1 suppression, showing synergy between mitoxantrone and telaglenastat in vitro and in vivo.

This paper identifies syntabulin as a determinant of chemosensitivity in high-grade serous ovarian cancer by linking mitochondrial metabolism and mitotic fidelity.